Description
Mebespalin Pharmacodynamics
A myotropic antispasmodic, it has direct action on the smooth muscles of the gastrointestinal tract without affecting normal intestinal peristalsis The exact mechanism of action is unknown, but multiple mechanisms, such as reduction in ion channel permeability, blockade of noradrenaline reuptake, local anesthetic action, and changes in water absorption, may cause local action of mebeverine on the gastrointestinal tract. Through these mechanisms, mebeverine has an antispasmodic effect, normalizing intestinal peristalsis without causing permanent relaxation of gastrointestinal smooth muscle cells (“hypotonia”). There are no systemic side effects, including anticholinergic.
Indications
Symptomatic treatment of pain, cramps, dysfunction and discomfort in the bowel area associated with irritable bowel syndrome
Symptoms may include: abdominal pain, cramps, feeling of bloating and flatulence, change in stool frequency (diarrhea, constipation or alternation of diarrhea and constipation), change in stool consistency.
Contraindications
– Hypersensitivity to any component of the drug.
– Age under 18 years.
– Congenital lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.
– Pregnancy and breast-feeding.
Administration during pregnancy and breast-feeding, effects on fertility.
Pregnancy: only very limited data are available on the use of mebeverine in pregnant women. There are insufficient animal studies to assess reproductive toxicity. The use of mebeverine during pregnancy is not recommended.
Breastfeeding period: information about the excretion of meberine or its metabolites in breast milk is insufficient. Studies of mebeverine excretion into milk in animals have not been conducted. Mebeverine should not be taken during breastfeeding
Fertility: there are no clinical data on the effect of the drug on fertility in men or women, but known animal studies have not demonstrated adverse effects of mebeverine.
Dosage and administration
- Oral.
- The tablets should be swallowed without chewing, with plenty of water (at least 100 ml).
- One tablet 3 times a day, about 20 minutes before a meal.
- The duration of intake of the drug is not limited.
- If a patient forgets to take one or more doses, the drug should be continued with the next dose. Do not take one or more missed doses in addition to the usual dose.
- Dosing regimen studies in elderly patients, patients with renal and/or hepatic impairment have not been conducted. The available data on the post-marketing use of the drug did not reveal any specific risk factors for its use in elderly patients and patients with renal and/or hepatic impairment. There is no need to change the dosing regimen in elderly patients and patients with renal and/or hepatic impairment.
